Inmaculada Ramírez-Macías

Dr. Inmaculada Ramírez-Macías

CIBERCV, Madrid, Spain.
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2011 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MSManuel Sánchez-Moreno
Manuel Sánchez-Moreno
FGFernando Gómez-Contreras
Fernando Gómez-Contreras
PNPilar Navarro
Pilar Navarro
CMClotilde Marín
Clotilde Marín
Inmaculada Ramírez-MacíasInmaculada Ramírez-Macías
Inmaculada Ramírez-Macías
MYMaría J. R. Yunta
María J. R. Yunta
To evaluate the in vitro leishmanicidal activity of imidazole-based (1–4) and pyrazole-based (5–6) benzo[g]phthalazine derivatives against Leishmania infantum and Leishmania braziliensis. The in vitro activity of compounds 1–6 was assayed on extracellular promastigote and axenic amastigote forms, and on intracellular amastigote forms of the parasites. Infectivity and cytotoxicity tests were performed on J774.2 macrophage cells using meglumine antimoniate (Glucantime) as the reference drug. The mechanisms of action were analysed by iron superoxide dismutase (Fe-SOD) and copper/zinc superoxide dismutase (CuZn-SOD) inhibition, metabolite excretion and transmission electronic microscopy (TEM). Compounds 1–6 were more active and less toxic than meglumine antimoniate. Data on infection rates and amastigote mean numbers showed that 2, 4 and 6 were more active than 1, 3 and 5 in both L. infantum and L. braziliensis. The inhibitory effect of these compounds on the antioxidant enzyme Fe-SOD of promastigote forms of the parasites was remarkable, whereas inhibition of human CuZn-SOD was negligible. The ultrastructural alterations observed in treated promastigote forms confirmed the greater cell damage caused by the most active compounds 2, 4 and 6. The modifications observed by 1H-NMR in the nature and amounts of catabolites excreted by the parasites after treatment with 1–6 suggested that the catabolic mechanisms could depend on the structure of the side chains linked to the benzo[g]phthalazine moiety. All the compounds assayed were active in vitro against the two Leishmania species and were less toxic against mammalian cells than the reference drug, but the monosubstituted compounds were significantly more effective and less toxic than their disubstituted counterparts.

9 September 2019 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
MEMaría Asunción Esteve-Pastor
María Asunción Esteve-Pastor
VRVanessa Roldán
Vanessa Roldán
JRJosé Miguel Rivera-Caravaca
José Miguel Rivera-Caravaca
Inmaculada Ramírez-MacíasInmaculada Ramírez-Macías
Inmaculada Ramírez-Macías
Gregory LipGregory Lip
Gregory Lip
FMFrancisco Marin
Francisco Marin
In cardiovascular disease (CVD), biomarkers (i.e., “biological markers”) could have multiple roles in understanding the complexity of cardiovascular (CV) pathophysiology and to offer an integrated approach to management. Biomarkers could help in daily practice as a diagnostic tool, to monitor therapy response, to assess prognosis and as early marker of CV damage, or to stratify risk. In recent years, the role of biomarkers in CVD is even more relevant and some have recently been included in clinical management guideline recommendations. The aim of this review is to discuss the recommendations in clinical guidelines of various biomarkers and to review their usefulness in daily clinical practice. Ultimately, a balance is needed between simplicity and practicality for clinical decision-making. Most biomarkers (whether blood, urine, or imaging-based) will improve on clinical risk stratification, but awaiting biomarker results may lead to delays in the initiation of therapy, for example, anticoagulation for stroke prevention in atrial fibrillation. Many biomarkers are nonspecific, being predictive of many CV and non-CV outcomes, so would be better as “rule-out” rather than “rule-in” assessments. Derivation of some biomarkers have also been made in highly selected clinical trial cohorts, where measurement is made at baseline but outcomes determined many years later; given the dynamic nature of risk in the “real world” where patients get older and develop incident risk factors, this may give a false impression of the risk profile. Finally, some laboratory biomarkers have a diurnal variation and inter-/intravariability (and lower limits of detection) in assays, which may be expensive, are added considerations.

5 April 2011 in Journal of Natural Products
Verified
Journal Article
Closed access
CMClotilde Marín
Clotilde Marín
Inmaculada Ramírez-MacíasInmaculada Ramírez-Macías
Inmaculada Ramírez-Macías
ALAngeles López-Céspedes
Angeles López-Céspedes
FOFrancisco Olmo
Francisco Olmo
NVNoelia Villegas
Noelia Villegas
MSManuel Sánchez-Moreno
Manuel Sánchez-Moreno

22 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FOFrancisco Olmo
Francisco Olmo
CRCarmen Rotger
Carmen Rotger
Inmaculada Ramírez-MacíasInmaculada Ramírez-Macías
Inmaculada Ramírez-Macías
LMLuis Martínez
Luis Martínez
CMClotilde Marín
Clotilde Marín
ACAntonio Costa
Antonio Costa

1 October 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ANA B. CABALLEROANA B. CABALLERO
ANA B. CABALLERO
Antonio Rodriguez-DieguezAntonio Rodriguez-Dieguez
Antonio Rodriguez-Dieguez
MQMiguel Quirós
Miguel Quirós
JSJuan M. Salas
Juan M. Salas
ÓHÓscar Huertas
Óscar Huertas
MSManuel Sánchez-Moreno
Manuel Sánchez-Moreno

13 January 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSManuel Sánchez-Moreno
Manuel Sánchez-Moreno
ASAna M. Sanz
Ana M. Sanz
FGFernando Gómez-Contreras
Fernando Gómez-Contreras
PNPilar Navarro
Pilar Navarro
CMClotilde Marín
Clotilde Marín
MYMaría J. R. Yunta
María J. R. Yunta